Allen D. R., A. Bolt, G. A. Chapman, R. L. Knight, J.
W. G. Meissner, D. A. Owen and R. J. Watson
(2007). Identification and structure–activity
relationships of 1‐aryl‐3‐piperidin‐4‐yl‐urea
derivatives as CXCR3 receptor antagonists,
Bioorganic & Medicinal Chemistry Letters
17(3): 697‐701.
Ansari K. F. and C. Lal (2009). Synthesis and
evaluation of some new benzimidazole
derivatives as potential antimicrobial agents,
European Journal of Medicinal Chemistry
44(5): 2294‐2299.
Budriesi R., P. Ioan, A. Locatelli, S. Cosconati, A.
Leoni, M. P. Ugenti, A. Andreani, R. Di Toro,
A. Bedini, S. Spampinato, L. Marinelli, E.
Novellino and A. Chiarini (2008). Imidazo[2,1‐
b]thiazole System: A Scaffold Endowing
Dihydropyridines with Selective
Cardiodepressant Activity, Journal of
Medicinal Chemistry 51(6): 1592‐1600.
Cole A. G., I. L. Stroke, M.‐R. Brescia, S. Simhadri,
J. J. Zhang, Z. Hussain, M. Snider, C. Haskell, S.
Ribeiro, K. C. Appell, I. Henderson and M. L.
Webb (2006). Identification and initial
evaluation of 4‐N‐aryl‐[1,4]diazepane ureas
as potent CXCR3 antagonists, Bioorganic &
Medicinal Chemistry Letters 16(1): 200‐203.
Dai Y., K. Hartandi, Z. Ji, A. A. Ahmed, D. H.
Albert, J. L. Bauch, J. J. Bouska, P. F.
Bousquet, G. A. Cunha and K. B. Glaser
(2007). Discovery of N‐(4‐(3‐Amino‐1 Hindazol‐
4‐yl) phenyl)‐N'‐(2‐fluoro‐5‐
methylphenyl) urea (ABT‐869), a 3‐
Aminoindazole‐Based Orally Active
Multitargeted Receptor Tyrosine Kinase
Inhibitor, Journal of medicinal chemistry
50(7): 1584‐1597.
de Oliveira Lopes R., N. C. Romeiro, C. K. F. de
Lima, L. L. da Silva, A. L. P. de Miranda, P. G.
B. Nascimento, F. Q. Cunha, E. J. Barreiro and
L. M. Lima (2012). Docking, synthesis and
pharmacological activity of novel ureaderivatives
designed as p38 MAPK inhibitors,
European journal of medicinal chemistry 54:
264‐271.
Demain A. L. and S. Sanchez (2009). Microbial
drug discovery: 80 years of progress, The
Journal of antibiotics 62(1): 5‐16.
Doğan S. D., E. Demirpolat, M. B. Y. Aycan and
M. Balci (2015). Synthesis of new 4‐azaindoles
via acyl azides, Tetrahedron 71(2):
252‐258.
Garudachari B., M. N. Satyanarayana, B.
Thippeswamy, C. K. Shivakumar, K. N.
Shivananda, G. Hegde and A. M. Isloor (2012).
Synthesis, characterization and antimicrobial
studies of some new quinoline incorporated
benzimidazole derivatives, European Journal
of Medicinal Chemistry 54: 900‐906.
Hodge C. N., P. E. Aldrich, L. T. Bacheler, C.‐H.
Chang, C. J. Eyermann, S. Garber, M. Grubb,
D. A. Jackson, P. K. Jadhav, B. Korant, P. Y. S.
Lam, M. B. Maurin, J. L. Meek, M. J. Otto, M.
M. Rayner, C. Reid, T. R. Sharpe, L. Shum, D.
L. Winslow and S. Erickson‐Viitanen (1996).
Improved cyclic urea inhibitors of the HIV‐1
protease: synthesis, potency, resistance
profile, human pharmacokinetics and X‐ray
crystal structure of DMP 450, Chemistry &
Biology 3(4): 301‐314.
Kashaw S. K., V. Kashaw, P. Mishra, N. K. Jain and
J. P. Stables (2009). Synthesis, anticonvulsant
and CNS depressant activity of some new
bioactive 1‐(4‐substituted‐phenyl)‐3‐(4‐oxo‐2‐
phenyl/ethyl‐4H‐quinazolin‐3‐yl)‐urea,
European Journal of Medicinal Chemistry
44(11): 4335‐4343.
Kryshchyshyn A., D. Atamanyuk and R. Lesyk
(2012). Fused thiopyrano [2, 3‐d] thiazole
derivatives as potential anticancer agents,
Scientia pharmaceutica 80(3): 509.
Lam P., P. Jadhav, C. J. Eyermann, C. N. Hodge, Y.
Ru, L. T. Bacheler, J. L. Meek, M. J. Otto, M.
M. Rayner and Y. N. Wong (1994). Rational
design of potent, bioavailable, nonpeptide
cyclic ureas as HIV protease inhibitors,
Science 263(5145): 380‐384.
Luzina E. L. and A. V. Popov (2009). Synthesis
and anticancer activity of Nbis(
trifluoromethyl)alkyl‐N′‐thiazolyl and Nbis(
trifluoromethyl)alkyl‐N′‐benzothiazolyl
ureas, European Journal of Medicinal
Chemistry 44(12): 4944‐4953.
Malla Reddy V. and K. Ravinder Reddy (2010).
Synthesis and antimicrobial activity of some
novel 4‐(1H‐benz [d] imidazol‐2yl)‐1, 3‐
thiazol‐2‐amines, Chemical and
Pharmaceutical Bulletin 58(7): 953‐956.
Millan D. S., M. E. Bunnage, J. L. Burrows, K. J.
Butcher, P. G. Dodd, T. J. Evans, D. A.
Fairman, S. J. Hughes, I. C. Kilty, A. Lemaitre,
R. A. Lewthwaite, A. Mahnke, J. P. Mathias, J.
Philip, R. T. Smith, M. H. Stefaniak, M. Yeadon
and C. Phillips (2011). Design and Synthesis of
Inhaled p38 Inhibitors for the Treatment of
Chronic Obstructive Pulmonary Disease,
Journal of Medicinal Chemistry 54(22): 7797‐
7814.
Motohashi N., M. Kawase, T. Kurihara, A. Hever,
S. Nagy, I. Ocsocvszki, M. Tanaka and J.
Molnar (1995). Synthesis and antitumor
activity of 1‐[2‐(chloroethyl)‐3‐(2‐substituted‐
10H‐phenothiazin‐10‐yl) alkyl‐1‐urea s as
potent anticancer agents, Anticancer research
16(5A): 2525‐2532.
Özcan S., E. Şahin and M. Balci (2007). The
synthesis of unusual isocoumarin derivatives:
the chemistry of homophthalic acid,
Tetrahedron letters 48(12): 2151‐2154.
Ramprasad J., N. Nayak, U. Dalimba, P.
Yogeeswari, D. Sriram, S. K. Peethambar, R.
Achur and H. S. S. Kumar (2015). Synthesis
and biological evaluation of new imidazo[2,1‐
b][1,3,4]thiadiazole‐benzimidazole
derivatives, European Journal of Medicinal
Chemistry 95: 49‐63.
Reddy T. S., H. Kulhari, V. G. Reddy, V. Bansal, A.
Kamal and R. Shukla (2015). Design, synthesis
and biological evaluation of 1,3‐diphenyl‐1Hpyrazole
derivatives containing
benzimidazole skeleton as potential
anticancer and apoptosis inducing agents,
European Journal of Medicinal Chemistry 101:
790‐805.
Regan J., S. Breitfelder, P. Cirillo, T. Gilmore, A.
G. Graham, E. Hickey, B. Klaus, J. Madwed, M.
Moriak, N. Moss, C. Pargellis, S. Pav, A. Proto,
A. Swinamer, L. Tong and C. Torcellini (2002).
Pyrazole Urea‐Based Inhibitors of p38 MAP
Kinase: From Lead Compound to Clinical
Candidate, Journal of Medicinal Chemistry
45(14): 2994‐3008.
Regan J., A. Capolino, P. F. Cirillo, T. Gilmore, A.
G. Graham, E. Hickey, R. R. Kroe, J. Madwed,
M. Moriak, R. Nelson, C. A. Pargellis, A.
Swinamer, C. Torcellini, M. Tsang and N.
Moss (2003). Structure−Acvity Relaonships
of the p38α MAP Kinase Inhibitor 1‐(5‐tert‐
Butyl‐2‐p‐tolyl‐2H‐pyrazol‐3‐yl)‐3‐[4‐(2‐
morpholin‐4‐yl‐ethoxy)naph‐ thalen‐1‐yl]urea
(BIRB 796), Journal of Medicinal Chemistry
46(22): 4676‐4686.
Seenaiah D., P. R. Reddy, G. M. Reddy, A.
Padmaja, V. Padmavathi and N. Siva krishna
(2014). Synthesis, antimicrobial and cytotoxic
activities of pyrimidinyl benzoxazole,
benzothiazole and benzimidazole, European
Journal of Medicinal Chemistry 77: 1‐7.
Shingalapur R. V., K. M. Hosamani and R. S. Keri
(2009). Synthesis and evaluation of in vitro
anti‐microbial and anti‐tubercular activity of
2‐styryl benzimidazoles, European Journal of
Medicinal Chemistry 44(10): 4244‐4248.
Sobol E., B. Yagen, H. Steve White, K. S. Wilcox, J.
G. Lamb, O. Pappo, B. J. Wlodarczyk, R. H.
Finnell and M. Bialer (2006). Preclinical
evaluation of 2,2,3,3‐
tetramethylcyclopropanecarbonyl‐urea, a
novel, second generation to valproic acid,
antiepileptic drug, Neuropharmacology 51(4):
933‐946.
Trivedi B. K., A. Holmes, T. L. Stoeber, C. J.
Blankley, W. H. Roark, J. A. Picard, M. K.
Shaw, A. D. Essenburg, R. L. Stanfield and B.
R. Krause (1993). Inhibitors of acyl‐
CoA:cholesterol acyltransferase. 4. A novel
series of urea ACAT inhibitors as potential
hypocholesterolemic agents, Journal of
Medicinal Chemistry 36(22): 3300‐3307.
Tunçbilek M., T. Kiper and N. Altanlar (2009).
Synthesis and in vitro antimicrobial activity of
some novel substituted benzimidazole
derivatives having potent activity against
MRSA, European Journal of Medicinal
Chemistry 44(3): 1024‐1033.
Vu C. B., J. E. Bemis, J. S. Disch, P. Y. Ng, J. J.
Nunes, J. C. Milne, D. P. Carney, A. V. Lynch, J.
J. Smith, S. Lavu, P. D. Lambert, D. J. Gagne,
M. R. Jirousek, S. Schenk, J. M. Olefsky and R.
B. Perni (2009). Discovery of Imidazo[1,2‐
b]thiazole Derivatives as Novel SIRT1
Activators, Journal of Medicinal Chemistry
52(5): 1275‐1283.
Wilde R. G., J. D. Klaczkiewicz, J. T. Billheimer, R.
R. Wexler and P. J. Gillies (1995). Acyl
CoA:cholesterol acyltransferase (ACAT)
inhibitors: heterocyclic bioisosteres for the
urea group in DuP 128, Bioorganic &
Medicinal Chemistry Letters 5(2): 177‐180.
Yang Y., Y. Shen, H. Liu and X. Yao (2011).
Molecular Dynamics Simulation and Free
Energy Calculation Studies of the Binding
Mechanism of Allosteric Inhibitors with p38α
MAP Kinase, Journal of Chemical Information
and Modeling 51(12): 3235‐3246.
Zhang H.‐Z., G. L. V. Damu, G.‐X. Cai and C.‐H.
Zhou (2013). Design, synthesis and
antimicrobial evaluation of novel
benzimidazole type of Fluconazole analogues
and their synergistic effects with
Chloromycin, Norfloxacin and Fluconazole,
European Journal of Medicinal Chemistry 64:
329‐344.
Zheng S., Q. Zhong, Y. Xi, M. Mottamal, Q. Zhang,
R. L. Schroeder, J. Sridhar, L. He, H. McFerrin
and G. Wang (2014). Modification and
Biological Evaluation of Thiazole Derivatives
as Novel Inhibitors of Metastatic Cancer Cell
Migration and Invasion, Journal of Medicinal
Chemistry 57(15): 6653‐6667.
Allen D. R., A. Bolt, G. A. Chapman, R. L. Knight, J.
W. G. Meissner, D. A. Owen and R. J. Watson
(2007). Identification and structure–activity
relationships of 1‐aryl‐3‐piperidin‐4‐yl‐urea
derivatives as CXCR3 receptor antagonists,
Bioorganic & Medicinal Chemistry Letters
17(3): 697‐701.
Ansari K. F. and C. Lal (2009). Synthesis and
evaluation of some new benzimidazole
derivatives as potential antimicrobial agents,
European Journal of Medicinal Chemistry
44(5): 2294‐2299.
Budriesi R., P. Ioan, A. Locatelli, S. Cosconati, A.
Leoni, M. P. Ugenti, A. Andreani, R. Di Toro,
A. Bedini, S. Spampinato, L. Marinelli, E.
Novellino and A. Chiarini (2008). Imidazo[2,1‐
b]thiazole System: A Scaffold Endowing
Dihydropyridines with Selective
Cardiodepressant Activity, Journal of
Medicinal Chemistry 51(6): 1592‐1600.
Cole A. G., I. L. Stroke, M.‐R. Brescia, S. Simhadri,
J. J. Zhang, Z. Hussain, M. Snider, C. Haskell, S.
Ribeiro, K. C. Appell, I. Henderson and M. L.
Webb (2006). Identification and initial
evaluation of 4‐N‐aryl‐[1,4]diazepane ureas
as potent CXCR3 antagonists, Bioorganic &
Medicinal Chemistry Letters 16(1): 200‐203.
Dai Y., K. Hartandi, Z. Ji, A. A. Ahmed, D. H.
Albert, J. L. Bauch, J. J. Bouska, P. F.
Bousquet, G. A. Cunha and K. B. Glaser
(2007). Discovery of N‐(4‐(3‐Amino‐1 Hindazol‐
4‐yl) phenyl)‐N'‐(2‐fluoro‐5‐
methylphenyl) urea (ABT‐869), a 3‐
Aminoindazole‐Based Orally Active
Multitargeted Receptor Tyrosine Kinase
Inhibitor, Journal of medicinal chemistry
50(7): 1584‐1597.
de Oliveira Lopes R., N. C. Romeiro, C. K. F. de
Lima, L. L. da Silva, A. L. P. de Miranda, P. G.
B. Nascimento, F. Q. Cunha, E. J. Barreiro and
L. M. Lima (2012). Docking, synthesis and
pharmacological activity of novel ureaderivatives
designed as p38 MAPK inhibitors,
European journal of medicinal chemistry 54:
264‐271.
Demain A. L. and S. Sanchez (2009). Microbial
drug discovery: 80 years of progress, The
Journal of antibiotics 62(1): 5‐16.
Doğan S. D., E. Demirpolat, M. B. Y. Aycan and
M. Balci (2015). Synthesis of new 4‐azaindoles
via acyl azides, Tetrahedron 71(2):
252‐258.
Garudachari B., M. N. Satyanarayana, B.
Thippeswamy, C. K. Shivakumar, K. N.
Shivananda, G. Hegde and A. M. Isloor (2012).
Synthesis, characterization and antimicrobial
studies of some new quinoline incorporated
benzimidazole derivatives, European Journal
of Medicinal Chemistry 54: 900‐906.
Hodge C. N., P. E. Aldrich, L. T. Bacheler, C.‐H.
Chang, C. J. Eyermann, S. Garber, M. Grubb,
D. A. Jackson, P. K. Jadhav, B. Korant, P. Y. S.
Lam, M. B. Maurin, J. L. Meek, M. J. Otto, M.
M. Rayner, C. Reid, T. R. Sharpe, L. Shum, D.
L. Winslow and S. Erickson‐Viitanen (1996).
Improved cyclic urea inhibitors of the HIV‐1
protease: synthesis, potency, resistance
profile, human pharmacokinetics and X‐ray
crystal structure of DMP 450, Chemistry &
Biology 3(4): 301‐314.
Kashaw S. K., V. Kashaw, P. Mishra, N. K. Jain and
J. P. Stables (2009). Synthesis, anticonvulsant
and CNS depressant activity of some new
bioactive 1‐(4‐substituted‐phenyl)‐3‐(4‐oxo‐2‐
phenyl/ethyl‐4H‐quinazolin‐3‐yl)‐urea,
European Journal of Medicinal Chemistry
44(11): 4335‐4343.
Kryshchyshyn A., D. Atamanyuk and R. Lesyk
(2012). Fused thiopyrano [2, 3‐d] thiazole
derivatives as potential anticancer agents,
Scientia pharmaceutica 80(3): 509.
Lam P., P. Jadhav, C. J. Eyermann, C. N. Hodge, Y.
Ru, L. T. Bacheler, J. L. Meek, M. J. Otto, M.
M. Rayner and Y. N. Wong (1994). Rational
design of potent, bioavailable, nonpeptide
cyclic ureas as HIV protease inhibitors,
Science 263(5145): 380‐384.
Luzina E. L. and A. V. Popov (2009). Synthesis
and anticancer activity of Nbis(
trifluoromethyl)alkyl‐N′‐thiazolyl and Nbis(
trifluoromethyl)alkyl‐N′‐benzothiazolyl
ureas, European Journal of Medicinal
Chemistry 44(12): 4944‐4953.
Malla Reddy V. and K. Ravinder Reddy (2010).
Synthesis and antimicrobial activity of some
novel 4‐(1H‐benz [d] imidazol‐2yl)‐1, 3‐
thiazol‐2‐amines, Chemical and
Pharmaceutical Bulletin 58(7): 953‐956.
Millan D. S., M. E. Bunnage, J. L. Burrows, K. J.
Butcher, P. G. Dodd, T. J. Evans, D. A.
Fairman, S. J. Hughes, I. C. Kilty, A. Lemaitre,
R. A. Lewthwaite, A. Mahnke, J. P. Mathias, J.
Philip, R. T. Smith, M. H. Stefaniak, M. Yeadon
and C. Phillips (2011). Design and Synthesis of
Inhaled p38 Inhibitors for the Treatment of
Chronic Obstructive Pulmonary Disease,
Journal of Medicinal Chemistry 54(22): 7797‐
7814.
Motohashi N., M. Kawase, T. Kurihara, A. Hever,
S. Nagy, I. Ocsocvszki, M. Tanaka and J.
Molnar (1995). Synthesis and antitumor
activity of 1‐[2‐(chloroethyl)‐3‐(2‐substituted‐
10H‐phenothiazin‐10‐yl) alkyl‐1‐urea s as
potent anticancer agents, Anticancer research
16(5A): 2525‐2532.
Özcan S., E. Şahin and M. Balci (2007). The
synthesis of unusual isocoumarin derivatives:
the chemistry of homophthalic acid,
Tetrahedron letters 48(12): 2151‐2154.
Ramprasad J., N. Nayak, U. Dalimba, P.
Yogeeswari, D. Sriram, S. K. Peethambar, R.
Achur and H. S. S. Kumar (2015). Synthesis
and biological evaluation of new imidazo[2,1‐
b][1,3,4]thiadiazole‐benzimidazole
derivatives, European Journal of Medicinal
Chemistry 95: 49‐63.
Reddy T. S., H. Kulhari, V. G. Reddy, V. Bansal, A.
Kamal and R. Shukla (2015). Design, synthesis
and biological evaluation of 1,3‐diphenyl‐1Hpyrazole
derivatives containing
benzimidazole skeleton as potential
anticancer and apoptosis inducing agents,
European Journal of Medicinal Chemistry 101:
790‐805.
Regan J., S. Breitfelder, P. Cirillo, T. Gilmore, A.
G. Graham, E. Hickey, B. Klaus, J. Madwed, M.
Moriak, N. Moss, C. Pargellis, S. Pav, A. Proto,
A. Swinamer, L. Tong and C. Torcellini (2002).
Pyrazole Urea‐Based Inhibitors of p38 MAP
Kinase: From Lead Compound to Clinical
Candidate, Journal of Medicinal Chemistry
45(14): 2994‐3008.
Regan J., A. Capolino, P. F. Cirillo, T. Gilmore, A.
G. Graham, E. Hickey, R. R. Kroe, J. Madwed,
M. Moriak, R. Nelson, C. A. Pargellis, A.
Swinamer, C. Torcellini, M. Tsang and N.
Moss (2003). Structure−Acvity Relaonships
of the p38α MAP Kinase Inhibitor 1‐(5‐tert‐
Butyl‐2‐p‐tolyl‐2H‐pyrazol‐3‐yl)‐3‐[4‐(2‐
morpholin‐4‐yl‐ethoxy)naph‐ thalen‐1‐yl]urea
(BIRB 796), Journal of Medicinal Chemistry
46(22): 4676‐4686.
Seenaiah D., P. R. Reddy, G. M. Reddy, A.
Padmaja, V. Padmavathi and N. Siva krishna
(2014). Synthesis, antimicrobial and cytotoxic
activities of pyrimidinyl benzoxazole,
benzothiazole and benzimidazole, European
Journal of Medicinal Chemistry 77: 1‐7.
Shingalapur R. V., K. M. Hosamani and R. S. Keri
(2009). Synthesis and evaluation of in vitro
anti‐microbial and anti‐tubercular activity of
2‐styryl benzimidazoles, European Journal of
Medicinal Chemistry 44(10): 4244‐4248.
Sobol E., B. Yagen, H. Steve White, K. S. Wilcox, J.
G. Lamb, O. Pappo, B. J. Wlodarczyk, R. H.
Finnell and M. Bialer (2006). Preclinical
evaluation of 2,2,3,3‐
tetramethylcyclopropanecarbonyl‐urea, a
novel, second generation to valproic acid,
antiepileptic drug, Neuropharmacology 51(4):
933‐946.
Trivedi B. K., A. Holmes, T. L. Stoeber, C. J.
Blankley, W. H. Roark, J. A. Picard, M. K.
Shaw, A. D. Essenburg, R. L. Stanfield and B.
R. Krause (1993). Inhibitors of acyl‐
CoA:cholesterol acyltransferase. 4. A novel
series of urea ACAT inhibitors as potential
hypocholesterolemic agents, Journal of
Medicinal Chemistry 36(22): 3300‐3307.
Tunçbilek M., T. Kiper and N. Altanlar (2009).
Synthesis and in vitro antimicrobial activity of
some novel substituted benzimidazole
derivatives having potent activity against
MRSA, European Journal of Medicinal
Chemistry 44(3): 1024‐1033.
Vu C. B., J. E. Bemis, J. S. Disch, P. Y. Ng, J. J.
Nunes, J. C. Milne, D. P. Carney, A. V. Lynch, J.
J. Smith, S. Lavu, P. D. Lambert, D. J. Gagne,
M. R. Jirousek, S. Schenk, J. M. Olefsky and R.
B. Perni (2009). Discovery of Imidazo[1,2‐
b]thiazole Derivatives as Novel SIRT1
Activators, Journal of Medicinal Chemistry
52(5): 1275‐1283.
Wilde R. G., J. D. Klaczkiewicz, J. T. Billheimer, R.
R. Wexler and P. J. Gillies (1995). Acyl
CoA:cholesterol acyltransferase (ACAT)
inhibitors: heterocyclic bioisosteres for the
urea group in DuP 128, Bioorganic &
Medicinal Chemistry Letters 5(2): 177‐180.
Yang Y., Y. Shen, H. Liu and X. Yao (2011).
Molecular Dynamics Simulation and Free
Energy Calculation Studies of the Binding
Mechanism of Allosteric Inhibitors with p38α
MAP Kinase, Journal of Chemical Information
and Modeling 51(12): 3235‐3246.
Zhang H.‐Z., G. L. V. Damu, G.‐X. Cai and C.‐H.
Zhou (2013). Design, synthesis and
antimicrobial evaluation of novel
benzimidazole type of Fluconazole analogues
and their synergistic effects with
Chloromycin, Norfloxacin and Fluconazole,
European Journal of Medicinal Chemistry 64:
329‐344.
Zheng S., Q. Zhong, Y. Xi, M. Mottamal, Q. Zhang,
R. L. Schroeder, J. Sridhar, L. He, H. McFerrin
and G. Wang (2014). Modification and
Biological Evaluation of Thiazole Derivatives
as Novel Inhibitors of Metastatic Cancer Cell
Migration and Invasion, Journal of Medicinal
Chemistry 57(15): 6653‐6667.
Doğan, Ş. D. (2016). N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi, 16(2), 222-229.
AMA
Doğan ŞD. N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi. April 2016;16(2):222-229.
Chicago
Doğan, Şengül Dilem. “N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi”. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi 16, no. 2 (April 2016): 222-29.
EndNote
Doğan ŞD (April 1, 2016) N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi 16 2 222–229.
IEEE
Ş. D. Doğan, “N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi”, Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi, vol. 16, no. 2, pp. 222–229, 2016.
ISNAD
Doğan, Şengül Dilem. “N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi”. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi 16/2 (April 2016), 222-229.
JAMA
Doğan ŞD. N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi. 2016;16:222–229.
MLA
Doğan, Şengül Dilem. “N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi”. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi, vol. 16, no. 2, 2016, pp. 222-9.
Vancouver
Doğan ŞD. N‐Aril‐N’‐Heteroaril‐Substitue Üre Türevlerinin Sentezi. Afyon Kocatepe Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi. 2016;16(2):222-9.